|
DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
|
DE10100586C1
(de)
|
2001-01-09 |
2002-04-11 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Ziegens
|
|
US7829693B2
(en)
|
1999-11-24 |
2010-11-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
|
US7423142B2
(en)
|
2001-01-09 |
2008-09-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
|
US8546143B2
(en)
|
2001-01-09 |
2013-10-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
|
US7745418B2
(en)
|
2001-10-12 |
2010-06-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting viral replication
|
|
DE10163098B4
(de)
|
2001-10-12 |
2005-06-02 |
Alnylam Europe Ag |
Verfahren zur Hemmung der Replikation von Viren
|
|
FR2832154B1
(fr)
|
2001-11-09 |
2007-03-16 |
Centre Nat Rech Scient |
Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
|
|
DE10202419A1
(de)
|
2002-01-22 |
2003-08-07 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
|
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US10011836B2
(en)
|
2002-11-14 |
2018-07-03 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
US8198427B1
(en)
|
2002-11-14 |
2012-06-12 |
Dharmacon, Inc. |
SiRNA targeting catenin, beta-1 (CTNNB1)
|
|
US8090542B2
(en)
|
2002-11-14 |
2012-01-03 |
Dharmacon Inc. |
Functional and hyperfunctional siRNA
|
|
US9719092B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting CNTD2
|
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
US9879266B2
(en)
|
2002-11-14 |
2018-01-30 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
US9771586B2
(en)
|
2002-11-14 |
2017-09-26 |
Thermo Fisher Scientific Inc. |
RNAi targeting ZNF205
|
|
US7619081B2
(en)
|
2002-11-14 |
2009-11-17 |
Dharmacon, Inc. |
siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
|
|
US7691998B2
(en)
|
2002-11-14 |
2010-04-06 |
Dharmacon, Inc. |
siRNA targeting nucleoporin 62kDa (Nup62)
|
|
US9839649B2
(en)
|
2002-11-14 |
2017-12-12 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
US7951935B2
(en)
|
2002-11-14 |
2011-05-31 |
Dharmacon, Inc. |
siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
|
|
US9719094B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting SEC61G
|
|
WO2006006948A2
(en)
|
2002-11-14 |
2006-01-19 |
Dharmacon, Inc. |
METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
|
|
US7612196B2
(en)
|
2002-11-14 |
2009-11-03 |
Dharmacon, Inc. |
siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
|
|
US7977471B2
(en)
|
2002-11-14 |
2011-07-12 |
Dharmacon, Inc. |
siRNA targeting TNFα
|
|
US7635770B2
(en)
|
2002-11-14 |
2009-12-22 |
Dharmacon, Inc. |
siRNA targeting protein kinase N-3 (PKN-3)
|
|
US7592442B2
(en)
|
2002-11-14 |
2009-09-22 |
Dharmacon, Inc. |
siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
|
|
GB0306148D0
(en)
*
|
2003-03-18 |
2003-04-23 |
Milner Jo |
Regulation of gene expression
|
|
KR20060013426A
(ko)
*
|
2003-05-30 |
2006-02-09 |
니뽄 신야쿠 가부시키가이샤 |
Bcl-2의 발현을 억제하는 올리고 이중쇄 RNA와그것을 함유하는 의약 조성물
|
|
NZ548254A
(en)
*
|
2003-12-23 |
2008-09-26 |
Santaris Pharma As |
Oligomeric compounds for the modulation of BCL-2
|
|
US20050244869A1
(en)
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
|
US7605250B2
(en)
|
2004-05-12 |
2009-10-20 |
Dharmacon, Inc. |
siRNA targeting cAMP-specific phosphodiesterase 4D
|
|
WO2006035432A2
(en)
*
|
2004-09-27 |
2006-04-06 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Gene silencing for use in dermatology
|
|
EP1937280B1
(en)
*
|
2005-09-12 |
2014-08-27 |
The Ohio State University Research Foundation |
Compositions for the therapy of bcl2-associated cancers
|
|
EP2487261B1
(en)
|
2006-01-05 |
2015-07-01 |
The Ohio State University Research Foundation |
MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
|
|
CA2646051A1
(en)
|
2006-03-20 |
2007-09-27 |
Carlo M. Croce |
Microrna fingerprints during human megakaryocytopoiesis
|
|
AU2007296055A1
(en)
*
|
2006-09-15 |
2008-03-20 |
Enzon Pharmaceuticals, Inc. |
Polymeric conjugates containing positively-charged moieties
|
|
CA2664271A1
(en)
*
|
2006-11-27 |
2008-06-12 |
Enzon Pharmaceuticals, Inc. |
Polymeric short interfering rna conjugates
|
|
JP2010519910A
(ja)
*
|
2007-03-02 |
2010-06-10 |
エムディーアールエヌエー,インコーポレイテッド |
Bcl2遺伝子の発現を抑制するための核酸化合物およびその使用
|
|
WO2008124927A1
(en)
*
|
2007-04-13 |
2008-10-23 |
Vincent Research & Consulting Inc. |
Sirna against thymidylate synthase and uses thereof in cancer treatment regimens
|
|
ES2570359T3
(es)
|
2007-08-03 |
2016-05-18 |
Univ Ohio State Res Found |
Regiones ultraconservadas que codifican ARNnc
|
|
WO2010006111A2
(en)
*
|
2008-07-10 |
2010-01-14 |
Merck & Co., Inc. |
Methods of using compositions comprising mir-192 and/or mir-215 for the treatment of cancer
|
|
WO2010021389A1
(ja)
*
|
2008-08-21 |
2010-02-25 |
協和発酵キリン株式会社 |
Bcl-2蛋白質の発現を抑制する核酸
|
|
GB2468477A
(en)
*
|
2009-03-02 |
2010-09-15 |
Mina Therapeutics Ltd |
Double stranded RNA molecule comprising siRNA and miRNA precursors
|
|
JP5960060B2
(ja)
|
2009-11-23 |
2016-08-02 |
ジ・オハイオ・ステート・ユニバーシティ |
腫瘍細胞の増殖、遊走および浸潤に影響を与えるために有用な物質および方法
|
|
ES2625689T3
(es)
|
2010-04-29 |
2017-07-20 |
Ionis Pharmaceuticals, Inc. |
Modulación de la expresión de transtiretina
|
|
WO2012027206A1
(en)
|
2010-08-24 |
2012-03-01 |
Merck Sharp & Dohme Corp. |
SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER
|
|
DK2632472T3
(en)
|
2010-10-29 |
2018-03-19 |
Sirna Therapeutics Inc |
RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
|
|
CA2816603A1
(en)
|
2010-11-12 |
2012-05-18 |
The Ohio State University Research Foundation |
Materials and methods related to microrna-21, mismatch repair, and colorectal cancer
|
|
EP2640368B1
(en)
|
2010-11-15 |
2020-12-30 |
The Ohio State University Research Foundation |
Controlled release mucoadhesive systems
|
|
CN104364390B
(zh)
|
2011-10-14 |
2016-08-24 |
俄亥俄州立大学 |
与卵巢癌相关的方法和材料
|
|
EP2790735A4
(en)
|
2011-12-13 |
2015-12-09 |
Ohio State Innovation Foundation |
METHODS AND COMPOSITIONS RELATING TO MIR-21 AND MIR-29A, EXOSOME INHIBITION, AND CANCER METASTASIS
|
|
CN104685065B
(zh)
|
2012-01-20 |
2017-02-22 |
俄亥俄州立大学 |
浸润性和预后的乳腺癌生物标志物标签
|
|
US9404108B2
(en)
|
2012-03-04 |
2016-08-02 |
Bonac Corporation |
Micro-RMA inhibitor
|
|
CN104781403A
(zh)
|
2012-10-05 |
2015-07-15 |
株式会社百奥尼 |
双调蛋白特异性-双螺旋寡核糖核苷酸,包含双螺旋寡核糖核苷酸的双螺旋寡核糖核苷酸结构,和包含以上成分的用于预防或治疗呼吸道疾病的组合物
|
|
CA2890725A1
(en)
*
|
2012-11-05 |
2014-05-08 |
Pronai Therapeutics, Inc. |
Methods of using biomarkers for the treatment of cancer by modulation of bcl2|expression
|
|
JP6426268B2
(ja)
|
2014-04-04 |
2018-11-21 |
バイオニア コーポレーションBioneer Corporation |
新規の二重らせんオリゴrnaおよびこれを含む線維症または呼吸器疾患の予防または治療用薬学組成物
|
|
KR101993377B1
(ko)
*
|
2017-07-20 |
2019-06-26 |
(주)큐리진 |
Bcl2 유전자 및 bi-1 유전자의 발현을 동시에 억제하는 핵산
|
|
CN113038956A
(zh)
*
|
2018-12-05 |
2021-06-25 |
日东电工株式会社 |
癌处置用RNAi分子
|
|
JPWO2020196736A1
(enExample)
*
|
2019-03-28 |
2020-10-01 |
|
|